BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, announced on Friday, the presentation of initial results from a phase two clinical trial at the Gastrointestinal Cancer Symposium, being held in San Francisco from 23 – 25 January 2020.

The presentation revealed details on the analysis of a Phase two clinical trial using BPM31510 in Pancreatic Ductal Adenocarcinoma (PDAC) refractory to present standard of care. Initial results indicated preliminary efficacy in patient's refractory to chemotherapy regimens and identification of potential biomarkers of survival guided by the use of the BERG Interrogative Biology platform.

Dr Niven R Narain, BERG co-founder, president and chief executive officer, said, 'Interrogative Biology has enabled BERG to unravel unique insight into interconnected pathways that drive cancer by mapping the nature of disease biology through patient data and Bayesian AI. The research presented this week at ASCO-GI further demonstrates how the BERG platform can enhance and improve development of treatments for pancreatic cancer through discovery and validation of biomarkers to improve patient outcomes.'